Anti-Pan-Acetyl-Lysine antibody [SMM5007] (STJ11106167)

SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG1
STJ11106167
๐Ÿšš Free UK Delivery on orders over ยฃ150
Processing The item has been added
Enquire For Bulk Order
✓ 1-Year Performance Guarantee | SDS & Datasheet Included | Expert Tech Support | Covered by St John's Laboratory Guarantee

General Information

Short DescriptionMouse monoclonal Pan-Acetyl-Lysine antibody for use in WB and ELISA in human, mouse, rat and other samples. Datasheet included with dilution recommendations, and related reagents.
ApplicationsWB/ELISA
HostMouse
ReactivityHuman/Mouse/Rat/Other
NoteSTRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.

Product Properties

ClonalityMonoclonal
Clone IDSMM5007
IsotypeIgG1
ConjugationUnconjugated
ConcentrationLot specific
PurificationAffinity purification
Dilution RangeWB:1:500-1:1000
ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements.
FormulationPBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3.

Target Information

SpecificityRecombinant fusion protein corresponding to a sequence containing acetylated K.

Additional Info

Background Acetylation of lysine, like phosphorylation of serine, threonine or tyrosine, is an important reversible modification controlling protein activity. The conserved amino-terminal domains of the four core histones (H2A, H2B, H3, and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (PMID: 9667866). Signaling resulting in acetylation/deacetylation of histones, transcription factors, and other proteins affects a diverse array of cellular processes including chromatin structure and gene activity, cell growth, differentiation, and apoptosis (PMID: 14593721). Recent proteomic surveys suggest that acetylation of lysine residues may be a widespread and important form of post-translational protein modification that affects thousands of proteins involved in control of cell cycle and metabolism, longevity, actin polymerization, and nuclear transport (PMID: 19608861). The regulation of protein acetylation status is impaired in cancer and polyglutamine diseases (PMID: 11864588) , and HDACs have become promising targets for anti-cancer drugs currently in development (PMID: 15032670).

Information sourced from Uniprot.org

Citations

Product Review